AIM: Among mothers undergoing BRCA1/2 testing and their spouses/partners, this study sought to examine decision support needs and motivations for family communication of genetic risk information to asymptomatic children. METHODS: This study gathered data from 213 tested mothers and 104 of their untested parenting partners 1 month after maternal receipt of genetic test results and upon making a decision about communicating genetic information to their child (ages 8-21 years). Data include parents' perceived needs for family communication decision support, decision motivations, and parent-child communication. RESULTS: Parents reported high decision support needs (e.g., educational materials, professional counseling, peer assistance). Motivations for disclosure to children among mothers and partners focused on promoting the parent-child bond and maintaining family health (55.3% and 75%, respectively) and promoting positive child affect (44.7% and 25.5%, respectively). Motivations for nondisclosure to children among mothers and partners focused on the lack of appropriateness (69.6% and 51.3%, respectively) and relative importance of genetic test results (30.4% and 48.7%, respectively). Significant discrepancies in parental motivation for family communication were observed. Decision support needs were highest among disclosing mothers with affect-related motivations [t (129)=2.47; p=0.01]. Parent-child communication was poorest among nondisclosing mothers concerned about the appropriateness of genetic information for their child [t (77)=-3.29; p=.002]. CONCLUSIONS: Parents receiving information about hereditary cancer predisposition have unmet needs when making decisions about disclosing genetic risk information to their asymptomatic children. These data can guide the development of cancer risk communication decision support interventions for parents undergoing such testing.
AIM: Among mothers undergoing BRCA1/2 testing and their spouses/partners, this study sought to examine decision support needs and motivations for family communication of genetic risk information to asymptomatic children. METHODS: This study gathered data from 213 tested mothers and 104 of their untested parenting partners 1 month after maternal receipt of genetic test results and upon making a decision about communicating genetic information to their child (ages 8-21 years). Data include parents' perceived needs for family communication decision support, decision motivations, and parent-child communication. RESULTS: Parents reported high decision support needs (e.g., educational materials, professional counseling, peer assistance). Motivations for disclosure to children among mothers and partners focused on promoting the parent-child bond and maintaining family health (55.3% and 75%, respectively) and promoting positive child affect (44.7% and 25.5%, respectively). Motivations for nondisclosure to children among mothers and partners focused on the lack of appropriateness (69.6% and 51.3%, respectively) and relative importance of genetic test results (30.4% and 48.7%, respectively). Significant discrepancies in parental motivation for family communication were observed. Decision support needs were highest among disclosing mothers with affect-related motivations [t (129)=2.47; p=0.01]. Parent-child communication was poorest among nondisclosing mothers concerned about the appropriateness of genetic information for their child [t (77)=-3.29; p=.002]. CONCLUSIONS: Parents receiving information about hereditary cancer predisposition have unmet needs when making decisions about disclosing genetic risk information to their asymptomatic children. These data can guide the development of cancer risk communication decision support interventions for parents undergoing such testing.
Authors: Angela R Bradbury; Linda Patrick-Miller; Brian Egleston; Colleen Burke Sands; Tianyu Li; Helen Schmidheiser; Maia Feigon; Comfort N Ibe; Fay J Hlubocky; Kisha Hope; Sarah Jackson; Melanie Corbman; Olufunmilayo I Olopade; Mary Daly; Christopher K Daugherty Journal: J Clin Oncol Date: 2010-06-21 Impact factor: 44.544
Authors: Eleanor L Cheung; Ashley D Olson; Tina M Yu; Pamela Z Han; Mary S Beattie Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-08-10 Impact factor: 4.254
Authors: Jordana Segal; Mary Jane Esplen; Brenda Toner; Sylvia Baedorf; Steven Narod; Kate Butler Journal: Am J Med Genet A Date: 2004-03-15 Impact factor: 2.802
Authors: Kenneth P Tercyak; Beth N Peshkin; Tiffani A Demarco; Andrea Farkas Patenaude; Katherine A Schneider; Judy E Garber; Heiddis B Valdimarsdottir; Marc D Schwartz Journal: Genet Test Date: 2007
Authors: Tiffani A Demarco; Rachel H Nusbaum; Beth N Peshkin; Andrea F Patenaude; Katherine A Schneider; Judy E Garber; Heiddis B Valdimarsdottir; Kenneth P Tercyak Journal: Patient Educ Couns Date: 2009-07-09
Authors: Darren Mays; Tiffani A DeMarco; George Luta; Beth N Peshkin; Andrea F Patenaude; Katherine A Schneider; Judy E Garber; Kenneth P Tercyak Journal: Health Psychol Date: 2013-06-24 Impact factor: 4.267
Authors: Kenneth P Tercyak; Darren Mays; Tiffani A DeMarco; Beth N Peshkin; Heiddis B Valdimarsdottir; Katherine A Schneider; Judy E Garber; Andrea Farkas Patenaude Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-07 Impact factor: 4.254
Authors: Kenneth P Tercyak; Suzanne M Bronheim; Nicole Kahn; Hillary A Robertson; Bruno J Anthony; Darren Mays; Suzanne C O'Neill; Susan K Peterson; Susan Miesfeldt; Beth N Peshkin; Tiffani A DeMarco Journal: Transl Behav Med Date: 2019-05-16 Impact factor: 3.046
Authors: Andrea Farkas Patenaude; Tiffani A DeMarco; Beth N Peshkin; Heiddis Valdimarsdottir; Judy E Garber; Katherine A Schneider; Larissa Hewitt; Jennifer Hamilton; Kenneth P Tercyak Journal: J Genet Couns Date: 2012-10-24 Impact factor: 2.537
Authors: Suzanne C O'Neill; Darren Mays; Andrea Farkas Patenaude; Judy E Garber; Tiffani A DeMarco; Beth N Peshkin; Katherine A Schneider; Kenneth P Tercyak Journal: J Community Genet Date: 2014-08-07
Authors: Lucy A Peipins; Juan L Rodriguez; Nikki A Hawkins; Ashwini Soman; Mary C White; M Elizabeth Hodgson; Lisa A DeRoo; Dale P Sandler Journal: J Womens Health (Larchmt) Date: 2018-01-29 Impact factor: 2.681